JP2025508832A - サイトカイン放出症候群の軽減のための投与レジメン - Google Patents

サイトカイン放出症候群の軽減のための投与レジメン Download PDF

Info

Publication number
JP2025508832A
JP2025508832A JP2024550167A JP2024550167A JP2025508832A JP 2025508832 A JP2025508832 A JP 2025508832A JP 2024550167 A JP2024550167 A JP 2024550167A JP 2024550167 A JP2024550167 A JP 2024550167A JP 2025508832 A JP2025508832 A JP 2025508832A
Authority
JP
Japan
Prior art keywords
dose
dosing regimen
subject
fraction
bispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508832A5 (cg-RX-API-DMAC7.html
Inventor
スリカンス・アール・アムバティ
アフィア・チョードリー
ヘシャム・モハメド
マズード・カクサール・トローギ
ミン・ヂゥ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2025508832A publication Critical patent/JP2025508832A/ja
Publication of JP2025508832A5 publication Critical patent/JP2025508832A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024550167A 2022-02-25 2023-02-24 サイトカイン放出症候群の軽減のための投与レジメン Pending JP2025508832A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263313932P 2022-02-25 2022-02-25
US63/313,932 2022-02-25
US202263393212P 2022-07-28 2022-07-28
US63/393,212 2022-07-28
US202263420782P 2022-10-31 2022-10-31
US63/420,782 2022-10-31
US202263424210P 2022-11-10 2022-11-10
US63/424,210 2022-11-10
US202363440304P 2023-01-20 2023-01-20
US63/440,304 2023-01-20
PCT/US2023/013836 WO2023164143A1 (en) 2022-02-25 2023-02-24 Dosing regimens for mitigation of cytokine release syndrome with odronextamab

Publications (2)

Publication Number Publication Date
JP2025508832A true JP2025508832A (ja) 2025-04-10
JP2025508832A5 JP2025508832A5 (cg-RX-API-DMAC7.html) 2026-02-27

Family

ID=85778997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550167A Pending JP2025508832A (ja) 2022-02-25 2023-02-24 サイトカイン放出症候群の軽減のための投与レジメン

Country Status (11)

Country Link
US (1) US20230272118A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482524A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508832A (cg-RX-API-DMAC7.html)
KR (1) KR20240167457A (cg-RX-API-DMAC7.html)
CN (1) CN119156226A (cg-RX-API-DMAC7.html)
AU (1) AU2023224098A1 (cg-RX-API-DMAC7.html)
CA (1) CA3244791A1 (cg-RX-API-DMAC7.html)
IL (1) IL315011A (cg-RX-API-DMAC7.html)
MX (1) MX2024010292A (cg-RX-API-DMAC7.html)
TW (1) TW202400228A (cg-RX-API-DMAC7.html)
WO (1) WO2023164143A1 (cg-RX-API-DMAC7.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN103533943B (zh) * 2010-11-10 2018-02-13 安进研发(慕尼黑)股份有限公司 由cd3特异性结合结构域导致的不良作用的预防
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
ES3009025T3 (en) * 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗cd20x抗cd3雙特異性抗體之穩定調配物

Also Published As

Publication number Publication date
MX2024010292A (es) 2024-12-06
IL315011A (en) 2024-10-01
US20230272118A1 (en) 2023-08-31
EP4482524A1 (en) 2025-01-01
CA3244791A1 (en) 2023-08-31
TW202400228A (zh) 2024-01-01
KR20240167457A (ko) 2024-11-26
CN119156226A (zh) 2024-12-17
AU2023224098A1 (en) 2024-09-12
WO2023164143A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US20230165959A1 (en) Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic Antibodies
JP2020528750A (ja) 抗ctla−4抗体およびその使用
JP2019503363A (ja) 急性リンパ芽球性白血病を治療するための二重特異性の抗cd20/抗cd3抗体
KR20180089444A (ko) 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합
KR20220110510A (ko) 이중특이적 항-BCMA x 항-CD3 항체를 이용한 다발성 골수종의 치료 방법
JP2026508624A (ja) 二重特異性抗cd22×抗cd28分子でがんを治療する方法
US20230272118A1 (en) Dosing Regimens for Mitigation of Cytokine Release Syndrome
RU2799529C2 (ru) Стратегия дозирования, уменьшающая синдром высвобождения цитокинов для биспецифичных антител к cd3/c20
HK40121299A (en) Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
HK40056070B (en) Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
HK40056070A (en) Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
WO2024081180A1 (en) Methods for reducing alloantibody levels in subjects in need of solid organ transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260218